UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): September 30, 2005
Urologix, Inc.
(Exact name of Registrant as Specified in its Charter)
Minnesota
(State Or Other Jurisdiction Of Incorporation)
| | |
| 000-28414 | | 41-1697237 |
| (Commission File Number) | | (I.R.S. Employer Identification No.) |
| | |
14405 21st Avenue North Minneapolis, MN | | 55447 |
| (Address Of Principal Executive Offices) | | (Zip Code) |
(763) 475-1400
Registrant’s Telephone Number, Including Area Code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Items under Sections 1-4 and 6-8 are not applicable and therefore omitted.
ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.
On September 30, 2005, Susan Bartlett Foote notified Urologix, Inc. (the “Company”) that she will not stand for re-election at the Company’s 2005 Annual Meeting of Shareholders. Ms. Foote intends to continue her term as a director until its expiration at the Annual Meeting of Shareholders in November 2005. Additionally, on October 3, 2005, the Board of Directors of the Company appointed Sidney W. Emery, Jr. as a director and named him as a nominee for election as a director at the 2005 Annual Meeting of Shareholders. The Board of Directors has not appointed Mr. Emery to serve on any committee of the Board at this time. Committee assignments will be reviewed by the Board of Directors following the 2005 Annual Meeting of Shareholders. Attached hereto as Exhibit 99.1 is a press release issued by the Company on October 5, 2005 relating to changes in the composition of the Board of Directors.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
| | |
Exhibit No.
| | Description
|
| 99.1 | | Press Release issued on October 5, 2005. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | |
| UROLOGIX, INC. |
| |
By: | | /s/ Fred B. Parks
|
| | | Fred B. Parks |
| | | Chief Executive Officer |
Date: October 5, 2005
